These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 10520679)
1. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group. Brophy JM; Joseph L; Theroux P Med Decis Making; 1999; 19(4):411-8. PubMed ID: 10520679 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799 [TBL] [Abstract][Full Text] [Related]
3. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis. Hiatt MD Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680 [TBL] [Abstract][Full Text] [Related]
4. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737 [TBL] [Abstract][Full Text] [Related]
5. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
6. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990 [TBL] [Abstract][Full Text] [Related]
7. Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. Califf RM; Stump D; Topol EJ; Mark DB Am Heart J; 1999 May; 137(5):S90-3. PubMed ID: 10220606 [No Abstract] [Full Text] [Related]
8. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. Massel D Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776 [TBL] [Abstract][Full Text] [Related]
9. Bayesian cost-effectiveness analysis. An example using the GUSTO trial. Fryback DG; Chinnis JO; Ulvila JW Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847 [TBL] [Abstract][Full Text] [Related]
10. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
11. [Platelet activation in the early phases of acute myocardial infarction]. Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873 [TBL] [Abstract][Full Text] [Related]
12. Emergent decision-making: defining the patient perspective. Knudtson ML Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261 [No Abstract] [Full Text] [Related]
13. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs. Tsui W; Pierre K; Massel D Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260 [TBL] [Abstract][Full Text] [Related]
14. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation. Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258 [No Abstract] [Full Text] [Related]
15. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
16. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA). Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130 [TBL] [Abstract][Full Text] [Related]
17. In-hospital and long-term prognostic value of fibrinogen, CRP, and IL-6 levels in patients with acute myocardial infarction treated with thrombolysis. Ziakas A; Gavrilidis S; Giannoglou G; Souliou E; Gemitzis K; Kalampalika D; Vayona MA; Pidonia I; Parharidis G; Louridas G Angiology; 2006; 57(3):283-93. PubMed ID: 16703188 [TBL] [Abstract][Full Text] [Related]
18. Safe use of thrombolysis in the elderly. Wittry MD; Thornton TA; Chaitman BR Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296 [TBL] [Abstract][Full Text] [Related]
19. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective. Heyland DK; Gafni A; Levine MA J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415 [TBL] [Abstract][Full Text] [Related]
20. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. Naylor CD; Armstrong PW CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]